Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outlook Therapeutics Inc.

https://outlooktherapeutics.com

Latest From Outlook Therapeutics Inc.

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion

New CEOs have been appointed at Cell Medica, Mologen, Navitor Pharmaceuticals, Tenaya Therapeutics and Oncobiologics, while a new CMO has been recruited to IGM Biosciences, a vice president of clinical development at Provention Bio and a CFO at Centrexion Therapeutics.

Appointments BioPharmaceutical

Humira Biosimilar Interchangeability: The Race Begins

Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Oncobiologics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Outlook Therapeutics Inc.
  • Senior Management
  • Lawrence A Kenyon, Pres., CEO & CFO
    Jeff Evanson, Chief Commercial Officer
    Kenneth Bahrt, MD, CMO
  • Contact Info
  • Outlook Therapeutics Inc.
    Phone: (609) 619-3990
    7 Clarke Dr.
    Cranbury, NJ 08512
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register